patritumab deruxtecan is composed of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide ...
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...
Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advance ...
In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab ...
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC ... of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based ...
Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of a protease-cleavable maleimide tetrapeptide and topoisomerase which is an exatecan derivative, produced in Chinese hamster ovary cells by ...
Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of a protease-cleavable maleimide tetrapeptide and topoisomerase which is an exatecan derivative, produced in Chinese hamster ovary cells by ...
Is Efficacious in Human Ovarian and Kidney Cancer Models DXd ADC is a novel ADC therapeutic designed with a potent DNA topoisomerase I inhibitor exatecan delivative. Raludotatug deruxtecan (R-DXd) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback